Pancreatic Adenocarcinoma

Oncology·MeSH: Mesothelioma, Malignant

Prevalence

7.1 / 100K

Incidence

7.5 / 100K/yr

23 drugs in development·10 companies·33 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
Zenocutuzumab (Zeno) / BIZENGRI® (zenocutuzumab-zbco)	Merus N.V. (MRUS)

Phase 3(8)

Drug	Company
ARM C FOLFIRI	IGM Biosciences, Inc. (IGMS)
Camrelizumab and Chemotherapy	Amneal Pharmaceuticals, Inc. (AMRX)
Chemotherapy	IGM Biosciences, Inc. (IGMS)
Chemotherapy	Amneal Pharmaceuticals, Inc. (AMRX)
Erlotinib Hydrochloride	Amneal Pharmaceuticals, Inc. (AMRX)
Folfirinox	Tango Therapeutics, Inc. (TNGX)
mFOLFIRINOX infusion	Tango Therapeutics, Inc. (TNGX)
panitumumab	GH Research PLC (GHRS)

Phase 2(8)

Drug	Company
Arm A - Olaparib	IGM Biosciences, Inc. (IGMS)
Dostarlimab	IGM Biosciences, Inc. (IGMS)
Gemzar	Zentalis Pharmaceuticals, Inc. (ZNTL)
HRS-4642+AG+Nimotuzumab	Merus N.V. (MRUS)
Niraparib	IGM Biosciences, Inc. (IGMS)
vcn-01	Theriva Biologics, Inc. (TOVX)
Veliparib	IGM Biosciences, Inc. (IGMS)
Zentalis	Zentalis Pharmaceuticals, Inc. (ZNTL)

Phase 1(3)

Drug	Company
Anetumab Ravtansine	ENANTA PHARMACEUTICALS INC (ENTA)
anti-pd-1	TriSalus Life Sciences Inc. (TLSI)
FOLFIRI	IGM Biosciences, Inc. (IGMS)

Phase 1/Phase 2(2)

Drug	Company
avelumab	VACCINEX, INC. (VCNX)
sd-101	TriSalus Life Sciences Inc. (TLSI)

Phase 4(1)

Drug	Company
Leucovorin Calcium	IGM Biosciences, Inc. (IGMS)

BioSniper tracks 23 drugs in development for Pancreatic Adenocarcinoma across 10 companies.

There are 33 clinical trials targeting Pancreatic Adenocarcinoma tracked by BioSniper.

The estimated prevalence of Pancreatic Adenocarcinoma is approximately 7.1 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.